Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Ronald J Fecek"'
Autor:
Yan Lin, Lisa H Butterfield, Pawel Kalinski, Walter J Storkus, Hussein Tawbi, Ahmad Tarhini, John M Kirkwood, Ronald J Fecek, Fei Ding, Lauren Miller, Deena Maurer, Manoj Chelvanambi, Amy Rose, Jennifer L Taylor, Anamika Bose, Devin Lowe, Melissa DeMark, Lilit Karapetyan, Jessica N Filderman, Timothy J Looney, Elizabeth Linch, Geoffrey M Lowman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 11 (2021)
Externí odkaz:
https://doaj.org/article/dcbb8fd4e95447ba88c7962ad61b4ed6
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 2 (2021)
Background The degree of immune infiltration in tumors, especially CD8+ T cells, greatly impacts patient disease course and response to interventional immunotherapy. Enhancement of tumor infiltrating lymphocyte (TIL) is a critical element of efficaci
Externí odkaz:
https://doaj.org/article/6af31dc7e11b473f951df255d7b2c68f
Autor:
Carolyn J. Anderson, Shubhanchi Nigam, Jennifer L. Taylor, Joseph D. Latoche, Ravi Patel, Fabio Gallazzi, Walter J. Storkus, Khanh-Van Ho, Robert S. Edinger, Lea Nyiranshuti, Ronald J Fecek, Kathryn Day, Michael Pun, Michael C Bellavia
Publikováno v:
Molecular Imaging and Biology. 24:425-433
PURPOSE Despite unprecedented responses to immune checkpoint inhibitors and targeted therapy in melanoma, a major subset of patients progresses and have few effective salvage options. We have previously demonstrated robust, selective uptake of the pe
Publikováno v:
SLAS Discov
We describe the development, optimization, and validation of 384-well growth inhibition assays for six patient-derived melanoma cell lines (PDMCLs), three wild type (WT) for BRAF and three with V600E-BRAF mutations. We conducted a pilot drug combinat
Autor:
Jennifer L. Taylor, Hussein Abdul-Hassan Tawbi, Lauren Miller, Jessica N. Filderman, Timothy J. Looney, Manoj Chelvanambi, John M. Kirkwood, Yan Lin, Deena M. Maurer, Melissa DeMark, Lilit Karapetyan, Ronald J Fecek, Walter J. Storkus, Anamika Bose, Lisa H. Butterfield, Geoffrey Lowman, Elizabeth Linch, Ahmad A. Tarhini, Devin B. Lowe, Fei Ding, Amy Rose, Pawel Kalinski
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 11 (2021)
Journal for immunotherapy of cancer, vol 9, iss 11
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 11 (2021)
Journal for immunotherapy of cancer, vol 9, iss 11
BackgroundA first-in-human, randomized pilot phase II clinical trial combining vaccines targeting overexpressed, non-mutated tumor blood vessel antigens (TBVA) and tyrosine kinase inhibitor dasatinib was conducted in human leukocyte antigen (HLA)-A2+
Autor:
Michael C, Bellavia, Lea, Nyiranshuti, Joseph D, Latoche, Khanh-Van, Ho, Ronald J, Fecek, Jennifer L, Taylor, Kathryn E, Day, Shubhanchi, Nigam, Michael, Pun, Fabio, Gallazzi, Robert S, Edinger, Walter J, Storkus, Ravi B, Patel, Carolyn J, Anderson
Publikováno v:
Mol Imaging Biol
PURPOSE: Despite unprecedented responses to immune checkpoint inhibitors and targeted therapy in melanoma, a major subset of patients progresses and have few effective salvage options. We have previously demonstrated robust, selective uptake of the p
Autor:
Nils Ludwig, Theresa L. Whiteside, Priyanka Sharma, Walter J. Storkus, Beatrice M. Razzo, Kellsye P Fabian, Ronald J Fecek, Chang-Sook Hong
Publikováno v:
Carcinogenesis
Circulating tumor-derived exosomes (TEX) interact with a variety of cells in cancer-bearing hosts, leading to cellular reprogramming which promotes disease progression. To study TEX effects on the development of solid tumors, immunosuppressive exosom
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 12 (2021)
Frontiers in Immunology, Vol 12 (2021)
Recent advances in immunotherapy have enabled rapid evolution of novel interventional approaches designed to reinvigorate and expand patient immune responses against cancer. An emerging approach in cancer immunology involves the conditional induction
Publikováno v:
J Control Release
Melanoma is the deadliest type of skin cancer with one of the fastest increasing incidence rates among solid tumors. The use of checkpoint inhibitors (e.g. αPD-1 antibody) has recently emerged as a viable alternative to conventional modes of therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fd2644bf34e963375918b3b0761e5c4
https://europepmc.org/articles/PMC7045464/
https://europepmc.org/articles/PMC7045464/